Icu Medical Inc/De (ICUI) Stock Price & Analysis
Icu Medical Inc/De (ICUI) rose 0.78% to USD 167.58 as of September 8, 2026 at 05:42 UTC, according to Nexqual real-time market data.
ICUI last closed at USD 166.29; the session ranged USD 164.8–167.87 on volume of 163,496 shares. Market capitalization is $4.19B, with a 52-week range of USD 112.5–192.85 (NMS). Source: Nexqual, September 8, 2026 at 05:42 UTC.
Key Statistics (as of September 8, 2026 at 05:42 UTC)
| Price | USD 167.58 |
|---|---|
| Change | ▲ 0.78% (up) |
| Previous Close | USD 166.29 |
| Open | USD 165.3 |
| Day Range | USD 164.8 – 167.87 |
| 52-Week Range | USD 112.5 – 192.85 |
| Volume | 163,496 shares |
| Market Cap | $4.19B |
| Exchange | NMS |
Technical Analysis (ICUI)
Nexqual's technical model rates ICUI "BUY" based on 4 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 42.16 (neutral) |
| vs SMA50 | Above (USD 167.22) |
| MACD | 0.32 (positive) |
Analyst Ratings (ICUI)
Wall Street analysts rate ICUI "None" based on 8 analysts, with a mean price target of USD 193.38 (range USD 178–210), per Nexqual as of September 8, 2026 at 05:42 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 193.38 |
| High Target | USD 210 |
| Low Target | USD 178 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (ICUI)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 2.15 |
| Revenue Estimate | $553.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.37 vs est 1.91 ▲ beat |
| 2026-03-31 | USD 1.97 vs est 1.75 ▲ beat |
| 2025-12-31 | USD 1.91 vs est 1.69 ▲ beat |
| 2025-09-30 | USD 2.03 vs est 1.43 ▲ beat |
Source: Nexqual, September 8, 2026 at 05:42 UTC.
Financials & Fundamentals (ICUI)
| Total Revenue | $2.16B |
|---|---|
| Revenue Growth (YoY) | +0.50% |
| Gross Margin | +38.26% |
| Operating Margin | +7.53% |
| Profit Margin | +1.39% |
| ROE | +1.41% |
| Debt / Equity | 59.82 |
| Current Ratio | 2.43 |
| Total Cash | $302.64M |
| Total Debt | $1.29B |
| Free Cash Flow | $163.56M |
Source: Nexqual, September 8, 2026 at 05:42 UTC.
Financial Health Score (ICUI)
Nexqual rates Icu Medical Inc/De's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 05:42 UTC.
| Growth | Weak — Revenue -7% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 38%, operating 8% |
| Balance Sheet | Strong — $303M cash vs $1.29B debt |
| Cash Flow | Solid — FCF $164M, 7% margin |
| Efficiency | Weak — ROE 1%, ROA 1.9% |
Ownership (ICUI)
| Insider Ownership | +1.75% |
|---|---|
| Institutional Ownership | +116.27% |
| Shares Outstanding | 25.01M |
| Float | 24.56M |
| Short % of Float | +6.63% |
Source: Nexqual, September 8, 2026 at 05:42 UTC.
Leadership (ICUI)
Icu Medical Inc/De is led by Vivek Jain (age 53), CEO & Chairman of the Board, per Nexqual as of September 8, 2026 at 05:42 UTC.
| CEO & Chairman of the Board | Vivek Jain (age 53) |
|---|---|
| President | Daniel Woolson (age 48) |
| CFO & Treasurer | Brian Michael Bonnell (age 51) |
| Chief Operating Officer | Christian B. Voigtlander (age 57) |
| Vice President of Human Resources | Olivia Barrall |
Major Backers & Investors (ICUI)
Notable institutional backers of Icu Medical Inc/De include Jupiter Topco LLC, JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund, Fuller & Thaler Asset Management Inc., according to Nexqual as of September 8, 2026 at 05:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 11.13% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 6.42% |
| Fuller & Thaler Asset Management Inc. | 5.19% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.22% |
| Schroder Investment Management Group | 2.96% |
| Ameriprise Financial, Inc. | 2.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.65% |
| Vanguard Group | 18.42% |
| Dimensional Fund Advisors | 4.21% |
| State Street | 4.1% |
Source: Nexqual, September 8, 2026 at 05:42 UTC.
From Icu Medical Inc/De's Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Our primary Infusion System products are: Large Volume Pump ("LVP") Hardware: • Plum Duo™ and Plum Solo™ precision infusion pumps (together, the "Plum precision pumps") are single-channel and dual-channel infusion pump systems that received FDA 510(k) clearance in April 2025.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MMSI | Merit Medical Systems, Inc. | USD 89.6 | ▼ 0.59% |
| HAE | Haemonetics Corporation | USD 102.92 | ▲ 0% |
| IART | Integra LifeSciences Holdings C | USD 16.72 | ▼ 0.54% |
| CNMD | CONMED Corporation | USD 49.32 | ▼ 0.22% |
| OFIX | Orthofix Medical Inc. | USD 9.29 | ▼ 0.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:42 UTC. This page is informational and not investment advice.